Oncotelic Therapeutics, Inc. (OTCMKTS:OTLC) Short Interest Update
by Mitch Edgeman · The Markets DailyOncotelic Therapeutics, Inc. (OTCMKTS:OTLC – Get Free Report) saw a large decline in short interest during the month of August. As of August 14th, there was short interest totaling 16 shares, a decline of 99.8% from the July 30th total of 9,551 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average trading volume of 322,731 shares, the short-interest ratio is presently 0.0 days.
Oncotelic Therapeutics Price Performance
OTLC stock traded down $0.00 during mid-day trading on Tuesday, hitting $0.03. The company had a trading volume of 163,434 shares, compared to its average volume of 172,338. The company has a 50-day moving average price of $0.04 and a 200 day moving average price of $0.04. Oncotelic Therapeutics has a 12-month low of $0.01 and a 12-month high of $0.11. The company has a market capitalization of $14.84 million, a price-to-earnings ratio of 0.06 and a beta of -0.23. The company has a quick ratio of 0.08, a current ratio of 0.08 and a debt-to-equity ratio of 0.01.
About Oncotelic Therapeutics
Oncotelic Therapeutics is a clinical‐stage biotechnology company dedicated to the development of novel oncolytic virotherapy and diagnostic platforms for cancer treatment. The company’s lead therapeutic candidate, telomelysin (OBP‐301), is an oncolytic adenovirus engineered to selectively replicate in telomerase‐positive tumor cells, offering a targeted approach to destroying cancerous tissue while sparing healthy cells. In addition to its therapeutic pipeline, Oncotelic markets TelomeScan, a proprietary diagnostic assay designed to detect and enumerate viable circulating tumor cells by exploiting telomerase activity.
Originally founded with technology licensed from Japanese research institutions, Oncotelic has established collaborative relationships in both the United States and Asia to advance its clinical and commercial programs.